RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

Spotlight on

Issue 44
Thirty years on, ESTRO remains focused on its vision for a cure
Issue 43
Unshackling progress in the care of childhood cancers
Issue 41
Where are the consensus guidelines for women with metastatic disease?
Issue 39
The Clinical Trials Directive: can we get it right the second time round?
Issue 33
Should we expect better from the media? A conversation with health journalists
Addicted to wonder drugs
Mass media's hit or myth approach to cancer
Issue 29
Europa Donna launches Breast Health Day
Issue 27
Bringing truths about cancer to new audiences: The UICC’s Reel Lives film festival showcases 33 of the best
Issue 25
Tackling cancer in the Middle East: Euro-Arab School of Oncology contributes a mix of international and local expertise
Issue 24
European leukaemia Network: making fragmentation a thing of the past
Issue 22
ECCO seeks heeling touch for oncology's lost voice
Issue 21
New breastcare network seeks to push up standards across the globe
Issue 20
ESO marks 25 years of championing excellence in cancer education
Issue 19
AACR marks 100 years of researching cancer
Issue 18
MRI directive threatens the care of Europe's cancer patients
Issue 17
What they never taught you at medical school
Issue 16
Not (just) another declaration
Closing the survival gap
Issue 15
Record-breaking stamp raises sticky questions
Helping the media to get the message
Issue 14
Quality cancer care 
ASCO and ESMO consensus statement
Issue12
Chernobyl 20 years on - the cancer incidence graphs are still rising
Putting cancer on the global agenda
Issue 10
Can science win back public trust?
FECS opens its doors to organ-based oncologists
Coming out for breast cancer, country by country
Issue 9
Radiotherapy report sets new targets for Europe
Issue 8
ESMO Minimum Clinical Recommendations
MEPs join forces against cancer
Issue 6
Rising to the challenge in the developing world  
Does your hospital pass the palliative care test?
Issue 5
Women doctors offer alternative to costly mammography 
Poorer countries take their place at the World Cancer Conference  
Issue 4
TITAN - Nurses to get frontline training in haematological toxicities
ESO: undergraduate courses - Inspiring the oncologists of tomorrow   
Issue 3
Flims: Building the next generation of clinical researchers  
Issue 2
EIO: A truly European Centre to rival the best 
Issue 1
EBCC: Driving up standards in breast care 

 
 

e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

GR16 - Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists (based on a review article of Critical Reviews in Oncology Hematology)

GR182 - Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

GR183 - The current management of low-grade glioma in childhood

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.